The retinal biologics market is expected to experience significant growth in the coming years, with its global size projected to surpass US$ 22.25 billion by 2022. Furthermore, the market is anticipated to continue its upward trend, reaching a valuation of US$ 41.92 billion by 2028, according to a recent market analysis. This rapid expansion is attributed to various factors, including advances in technology and a growing demand for effective treatments. The market is expected to register an impressive compound annual growth rate (CAGR) of 11.1% between 2022 and 2028.
Diabetes-related eye disorders and age-related macular degeneration (AMD) are becoming more common.
- Significant R&D resources are being invested in the development of biologics for infectious and non-infectious retinal disorders.
- Specific biologic molecules are increasingly being used as a promising therapeutic target.
- As a result of the huge number of monogenic retinal illnesses, gene therapy is being developed as a Retinal Biologic.
Request a Sample Report with Table of Content
https://www.futuremarketinsights.com/reports/sample/rep-gb-8663
Retinal Biologics Distribution in Specialty Clinics and Hospitals Prominent
Retinal Biologics manufacturers offer their goods through institutional and retail distribution channels. According to the FMI report, institutional sales in the Retinal Biologics market, where Retinal Biologics are supplied in speciality clinics and hospitals, will generate higher revenues. In 2018, hospital sales accounted for more than 35% of market revenue.
According to the report, retail sales of Retinal Biologics will generate comparable revenues to hospital sales and will expand at an 11.9% annual rate in 2019. Retail distribution takes place through retail pharmacies and mail order pharmacies, with retail pharmacies generating more money than their counterparts in the future years.
Penetration in North America Higher, APEJ’s Attractiveness to Increase
North America continues to be the market leader in Retinal Biologics revenue. According to FMI estimates, North America accounted for more than 46% of global Retinal Biologics market revenues in 2018. Revenues in North America are predicted to expand 10.4% year on year in 2019 due to an increase in the prevalence of retinal illnesses, continuous growth in the healthcare infrastructure, and a favourable reimbursement scenario.
Europe accounted for about one-fourth of the Retinal Biologics market, with Western European countries such as Germany, the United Kingdom, France, Italy, and Spain accounting for the majority of demand penetration. The APEJ Retinal Biologics market is predicted to grow at an 11% annual rate in 2019, with China and India remaining the most lucrative areas.
Retinal Biologics Find Prominent Use in Macular Degeneration Treatment
The study opines that over 35% of the Retinal Biologics revenues were consolidated in the treatment of macular degeneration. Highest revenue growth of 12.3% is also expected in macular degeneration as compared to other indications where Retinal Biologics are used in 2019.
Macular degeneration (MD) remains the leading cause of vision loss wherein it affects over 10 million Americans, the prevalence is higher than the combined incidences of cataract and glaucoma, as per the American Macular Degeneration Foundation (AMDF). As macular degeneration mainly affect people of age 50 years or more, with the ageing population, the prevalence of MD continues to rise despite improved treatment options.
Contact Sales for Further Assistance in Purchasing this Report
https://www.futuremarketinsights.com/checkout/8663
Key Players Covered In The Retinal Biologics Market:
- Spark Therapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceuticals, Inc.
- AbbVie Inc.
- Amgen Inc.
- Novartis Pharma AG
- MeiraGTx Limited
- Oxurion NV
- Santen Pharmaceutical Co., Ltd.
- Bayer AG
- Bausch Health Companies Inc.
- Merck & Co., Inc.
Key Segments of Retinal Biologics Industry Survey
Retinal Biologics Market by Drug Class:
- VEGF-A Antagonists
- TNF-α Inhibitors
Retinal Biologics Market by Indication:
- Macular Degeneration
- Diabetic Macular Edema
- Diabetic Retinopathy
- Uveitis
- Others
Retinal Biologics Market by Distribution Channel:
- Institutional Sales
- Retail Pharmacies
- Mail Order Pharmacies
- Retail Sales
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube